48. Parvin JD (2009) The BRCA1-dependent ubiquitin ligase, gamma-tubulin, and centrosomes. Environ Mol Mutagen 50: 649–653. 49. Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM (2000) Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc Natl Acad Sci U S A 97: 5208–5213. 50. Abramovitch S, Glaser T, Ouchi T, Werner H (2003) BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett 541: 149–154. 51. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71. 52. Cortez D, Wang Y, Qin J, Elledge SJ (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286: 1162–1166. 53. Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, et al. (2000) Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res 60: 3299–3304. 54. Gatei M, Zhou BB, Hobson K, Scott S, Young D, et al. (2001) Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem 276: 17276–17280. 55. Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston D, et al. (2000) Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 14: 2989–3002. 56. Lee HM, Flores E, Forchhammer K, Herrero A, Tandeau De Marsac N (2000) Phosphorylation of the signal transducer PII protein and an additional effector are required for the PII-mediated regulation of nitrate and nitrite uptake in the Cyanobacterium synechococcus sp. PCC 7942. Eur J Biochem 267: 591–600. 57. Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ (2006) A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 20: 2673–2686. 58. Man S, Munoz R, Kerbel RS (2007) On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev 26: 737–747. 59. Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249–289. 60. Arteaga CL, Dugger TC, Winnier AR, Forbes JT (1993) Evidence for a positive role of transforming growth factor-beta in human breast cancer cell tumorigenesis. J Cell Biochem Suppl 17G: 187–193. 61. Bedford MT, Richard S (2005) Arginine methylation an emerging regulator of protein function. Mol Cell 18: 263–272. BRCA1 Methylation 62. Wooderchak WL, Zang T, Zhou ZS, Acuna M, Tahara SM, et al. (2008) Substrate profiling of PRMT1 reveals amino acid sequences that extend beyond the ‘‘RGG’’ paradigm. Biochemistry 47: 9456–9466. 63. Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, et al. (1996) The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem 271: 32863–32868. 64. Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, et al. (1997) Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene 14: 1–16. 65. Rodriguez JA, Henderson BR (2000) Identification of a functional nuclear export sequence in BRCA1. J Biol Chem 275: 38589–38596. 66. Altiok S, Batt D, Altiok N, Papautsky A, Downward J, et al. (1999) Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/ AKT in breast cancer cells. J Biol Chem 274: 32274–32278. 67. Herrmann F, Fackelmayer FO (2009) Nucleo-cytoplasmic shuttling of protein arginine methyltransferase 1 (PRMT1) requires enzymatic activity. Genes Cells 14: 309–317. 68. Herrmann F, Lee J, Bedford MT, Fackelmayer FO (2005) Dynamics of human protein arginine methyltransferase 1(PRMT1) in vivo. J Biol Chem 280: 38005–38010. 69. Maor SB, Abramovitch S, Erdos MR, Brody LC, Werner H (2000) BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Genet Metab 69: 130–136. 70. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, et al. (2007) Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett 257: 236–243. 71. Maor S, Papa MZ, Yarden RI, Friedman E, Lerenthal Y, et al. (2007) Insulin- like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm Metab Res 39: 179–185. 72. Wilson DM, 3rd, Thompson LH (1997) Life without DNA repair. Proc Natl Acad Sci U S A 94: 12754–12757. 73. Akiyama K, Seki S, Oshida T, Yoshida MC (1994) Structure, promoter analysis and chromosomal assignment of the human APEX gene. Biochim Biophys Acta 1219: 15–25. 74. Ikeda S, Ayabe H, Mori K, Seki Y, Seki S (2002) Identification of the functional elements in the bidirectional promoter of the mouse O-sialoglycoprotein endopeptidase and APEX nuclease genes. Biochem Biophys Res Commun 296: 785–791. 75. Fung H, Bennett RA, Demple B (2001) Key role of a downstream specificity protein 1 site in cell cycle-regulated transcription of the AP endonuclease gene APE1/APEX in NIH3T3 cells. J Biol Chem 276: 42011–42017. 76. Higgins DG, Thompson JD, Gibson TJ (1996) Using CLUSTAL for multiple sequence alignments. Methods Enzymol 266: 383–402. PLoS ONE | www.plosone.org 12 June 2010 | Volume 5 | Issue 6 | e11379